Mylan says Teva's stake buy violates U.S. anti-trust rules

Mon Jun 1, 2015 6:01pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

(Reuters) - Mylan NV (MYL.O: Quote) said Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote) (TEVA.N: Quote), which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.

Teva disclosed a 1.35 percent stake in Mylan last week.

"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.(1.usa.gov/1Q0SxgC)

Mylan did not clarify which anti-trust rule Teva violated.

The two companies were not immediately available for comment.

Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)

 
A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. REUTERS/Ronen Zvulun